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Abstract 
In attempt to find new pharmacologically active molecules, we report here the 
synthesis and in vitro antimicrobial activity of various 3-(1,3,4-oxadiazol-2-yl)-
quinazolin-4(3H)-ones. The antimicrobial activity of title compounds were 
examined against two gram positive bacteria (S. aureus,  S. pyogenes), two 
gram negative bacteria (E. coli, P. aeruginosa) and three fungi (C. albicans, A. 
niger,  A. clavatus) using the broth microdilution method. Some derivatives 
bearing a bromo or iodo group exhibited very good antimicrobial activity. 
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Introduction 
The chemistry of heterocyclic compounds has been an interesting field of study for a long 
time. The synthesis of novel oxadiazole derivatives and investigation of their chemical and 
biological behavior have gained more importance in recent decades for biological, 
medicinal and agricultural reasons. 1,3,4-Oxadiazoles represent an important class of 
heterocyclic compounds. Their derivatives possess a broad spectrum of biological activity 
in both agrochemicals and pharmaceuticals such as insecticidal, herbicidal, antibacterial, 
antifungal, analgesic, anti-inflammatory, antimalarial, antiviral, anti-HBV, antianexiety, 
anticancer, anti-HIV, antitubercular and anticonvulsant [1–14]. Quinazolinone nucleus has 
been gaining prominence due to the fact that its derivatives have been found to possess 
wide spectrum of pharmacological properties. Quinazolin-4(3H)-one derivatives are useful 
heterocycles, possessing potent pharmacological activities such as antibacterial, 
antifungal, analgesic, anti-inflammatory, anthelminthic, anticancer, anticonvulsant, 172  N. B. Patel and J. C. Patel: 
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antihistaminic, anti-HIV, antiproliferative, antitubercular, antiviral, CNS depressant, 
cytotoxicity, diuretic and hypolipidemic [15–30]. 
1,3,4-Qxadiazoles and quinazolin-4(3H)-ones having various heterocycles possess wide 
range of pharmacological properties. The aim of the present work was to attach 
1,3,4-oxadiazole residues to quinazolin-4(3H)-one in order to find new biologically active 
molecules. Thus, the synthesis of novel 1,3,4-oxadiazolyl-quinazolin-4(3H)-one derivatives 
has been achieved. 
Results and Discussion 
Chemistry 
The title compounds 9a–f, 10a–f and 12a–f were synthesized according to Scheme 2. The 
structure of all the synthesized compounds were evaluated by spectral data. Benzoic acid 
derivatives 1a,b were converted in to esters 2a,b using methanol and catalytic amount of 
sulphuric acid. Esters 2a,b on treatment with hydrazine hydrate yielded corresponding 
hydrazides  3a,b. The IR spectra of 3a,b showed the absence of ester stretching 
frequency, instead in gave a band at around 1650 cm
−1 for carbonyl group and showing 
sharp bands in the region of 3300-3435 cm
−1 due to -NHNH2 group. Hydrazides on 
cyclization reaction with methanolic cyanogen bromide and 4-aminobenzoic acid in 
phosphorus oxychloride yielded amino substituted 1,3,4-oxadiazoles 4a,b and 5a,b 
respectively (Scheme 1). 1,3,4-oxadiazole showed C=N stretching at around 1655 cm
−1 
and C-O-C stretching at around 1270 cm
−1 and 1040 cm
−1. Signals at around 158 δ ppm 
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Substituted benzoxazinones 8a–c were prepared by reaction of acid chloride 6 with 
substituted anthranilic acid 7a–c in pyridine. Then condensation reaction of 8a–c with 
1,3,4-oxadiazoles  4a,b and 5a,b  yielded the desired compounds 9a–f and 10a–f. 
Substituted benzoxazinones 8a–c on reaction with glycine yielded quinazolin-4(3H)-ones 
11a–c which on cyclization reaction with hydrazides 3a,b gave the desired compounds 
12a–f (Scheme 2). IR spectra showed C=O and C=N stretching frequencies of 
quinazolinone at around 1680 cm
−1 and 1610 cm
−1 respectively, further confirmed by 
13C 
NMR spectra, which showed C=O and C=N signal at around 160.5 δ ppm and 163.5 δ 
ppm respectively. 
Antibacterial activity 
Tab. 1.   Antibacterial activity (MBC, μg/ml) of compounds 4a,b, 5a,b, 9a–f, 10a–f and 
12a–f. 
Gram positive bacteria  Gram negative bacteria 
S. aureus  S. pyogenes  E. coli  P. aeruginosa  Comp. R
1 R
2 
MTCC 96  MTCC 442  MTCC 443  MTCC 1688 
4a  2-Cl –  250  250  50  250 
4b  4-Cl –  200  250  250  500 
5a  2-Cl –  100  150  250  200 
5b  4-Cl –  200  250  500  500 
9a  2-Cl H  250  200  500  500 
9b  2-Cl Br  100  250  200  250 
9c  2-Cl I  500  500  100  250 
9d  4-Cl H  200  250  200  250 
9e  4-Cl Br  250  250  250  150 
9f  4-Cl I  500  1000  250  200 
10a  2-Cl H  150  250  500  500 
10b  2-Cl Br  500  1000  250  500 
10c  2-Cl I  100  150  150  500 
10d  4-Cl H  500  500  200  250 
10e  4-Cl Br  250  250  150  250 
10f  4-Cl I  62.5  150  100  250 
12a  2-Cl H  500  500  250  250 
12b  2-Cl Br  500  500  100  50 
12c  2-Cl I  50  250  125  200 
12d  4-Cl H  500  500  150  200 
12e  4-Cl Br  500  250  100  250 
12f  4-Cl I  200  200  50  150 
Ampicillin  – –  250  100  100  100 
 
The minimal bactericidal concentrations of the tested compounds are shown in Tab. 1. The 
three different series of 1,3,4-oxadiazolyl-quinazolin-4(3H)-ones  9a–f,  10a–f and 12a–f 
were tested for in vitro antibacterial activity against two gram positive bacteria (S. aureus 
MTCC 96, S. pyogenes MTCC 442) and two gram negative bacteria (E. coli MTCC 443, P. 
aeruginosa MTCC 1688). Ampicillin was used as a standard drug. Results showed that,   Synthesis and Antimicrobial Activity of 3-(1,3,4-Oxadiazol-2-yl)quinazolin-4(3H)-ones 175 
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most of the compounds possessed very good antibacterial activity (MBC = 50-250 μg/ml) 
against gram positive bacteria S. aureus. Some of the compounds possessed excellent 
activity as compared to ampicillin. Compounds 5a, 9b, 10a, 10c, 10f and 12c showed 
MBC value in the range between 50–150 μg/ml while standard drug ampicillin itself had 
MBC value of 250 μg/ml against gram positive bacteria S. aureus. Compounds 4a, 4b, 5b, 
9a, 9d, 9e, 10e and 12f imparted parallel activity as ampicillin with MBC in the range 200-
250 μg/ml. 5a, 10c and 10f have MBC at 150 μg/ml which were comparatively good as 
ampicillin against S. pyogenes. 4a and 12f showed excellent activity at 50 μg/ml while 9c, 
10f, 12b and 12e possessed good activity at 100 μg/ml against gram negative bacteria E. 
coli as compared to ampicillin. Compound 12b showed excellent activity at 50 μg/ml, while 
9e and 12f exhibited good activity at 150 μg/ml against P. aeruginosa. The remaining 
compounds of the three different series possessed moderate to poor activities. 
Antifungal activity 
Tab. 2.   Antifungal activity (MFC, μg/ml) of compds. 4a,b, 5a,b, 9a–f, 10a–f and 12a–f. 
Fungal species 
C. albicans  A. niger  A. clavatus  Comp. R
1 R
2 
MTCC 227  MTCC 282  MTCC 1323 
4a  2-Cl –  250  1000  1000 
4b  4-Cl –  >1000  >1000  >1000 
5a  2-Cl –  500  500  500 
5b  4-Cl –  500  >1000  >1000 
9a  2-Cl H  500  250  250 
9b  2-Cl Br  500  500  500 
9c  2-Cl I  500  500  >1000 
9d  4-Cl H  500  250  250 
9e  4-Cl Br  500  500  500 
9f  4-Cl I  250  200  200 
10a  2-Cl H  >1000  >1000  >1000 
10b  2-Cl Br  250  500  >1000 
10c  2-Cl I  >1000  >1000  >1000 
10d  4-Cl H  500  >1000  >1000 
10e  4-Cl Br  500  >1000  >1000 
10f  4-Cl I  250  500  500 
12a  2-Cl H  >1000  500  >1000 
12b  2-Cl Br  250  500  250 
12c  2-Cl I  100  200  200 
12d  4-Cl H  >1000  >1000  >1000 
12e  4-Cl Br  500  >1000  500 
12f  4-Cl I  200  >1000  500 
Griseofulvin  – –  500  100  100 
 
Minimal fungicidal concentrations of the synthesized compounds are shown in Table 2. For 
in vitro antifungal activity, three fungal species C. albicans MTCC 227, A. niger MTCC 282 
and A. clavatus MTCC 1323 were used and compared with standard drug griseofulvin. 
Most of the compounds possessed very good antifungal activity against C. albicans. Their 176  N. B. Patel and J. C. Patel: 
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MFC values are in the range between 100-500 μg/ml. Compound 12c showed excellent 
activity at 100 μg/ml whereas compounds 4a, 9f, 10b, 10f, 12b and 12f possessed very 
good activity at 200-250 μg/ml while 5a,b, 9a–e, 10d,e and 12e share similar activities as 
griseofulvin which was 500 μg/ml against C. albicans. Compounds 9a, 9d, 9f and 12c 
showed moderate activities with MFC of 200-250 μg/ml against A. niger and A. clavatus. 
The remaining compounds displayed poor activities against both fungal species A. niger 
and A. clavatus as compared to control drug griseofulvin. 
Experimental 
Chemistry 
All chemical were of analytical grade and used directly. Melting points were determined in 
PMP-DM scientific melting point apparatus and are uncorrected. IR spectra were recorded 
on a Perkin-Elmer RX 1 FTIR spectrophotometer, using potassium bromide pellets and the 
frequencies are expressed in cm
−1. The 
1H NMR and 
13C NMR spectra were recorded with 
a  Bruker Avance II 400 NMR spectrometer, using tetramethylsilane as the internal 
reference, with dimethylsulphoxide DMSO-d6 as solvent. The chemical shifts are reported 
in parts per million (ppm). Elemental analyses were performed on a Heraeus Carlo Erba 
1180 CHN analyzer. The purity of compounds was confirmed by TLC using Merck silica 
gel 60 F254 plates using toluene:ethylacetate:methanol (7:2:1) as a mobile phase and 
spots were visualized under UV radiation. {2-[(2,6-Dichlorophenyl)amino]phenyl}acetyl 
chloride (6) was synthesized by the literature procedure [31]. 
General procedure for esters (2a,b) 
Substituted benzoic acid 1a,b (20 mmol) and 30 ml methanol was refluxed on water bath 
for 5–8 h in a few drops of concentrated sulfuric acid as a catalyst. After completion of the 
reaction, it was poured onto ice cold water. The obtained solid was washed with sodium 
bicarbonate solution (5%), dried and recrystallized twice from methanol. 
Methyl 2-chlorobenzoate (2a) 
Yield: 75%, bp: 232–236°C. IR (KBr), v, cm
−1: 740 (C-Cl), 2856, 2960 (CH3), 1286, 1121 
(C-O-C), 1722 (C=O). 
Methyl 4-chlorobenzoate (2b) 
Yield: 72%, mp: 40–45°C. IR (KBr), v, cm
−1: 742 (C-Cl), 2852, 2959 (CH3), 1282, 1119 (C-
O-C), 1720 (C=O). 
General procedure for hydrazides (3a,b) 
To a solution of methyl benzoates 2a,b (10 mmol) in 15 ml methanol was added hydrazine 
hydrate (20 mmol). The reaction mixture was refluxed on a water bath for 8–10 h and 
allowed to stand overnight. The crystals formed were filtered, washed and after drying 
recrystallized from methanol. 
2-Chlorobenzohydrazide (3a) 
Yield: 70%, mp: 112–116°C. IR (KBr), v, cm
−1: 742 (C-Cl), 1650 (C=O), 3308 (NH), 3429, 
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4-Chlorobenzohydrazide (3b) 
Yield: 67%, mp: 163–166°C. IR (KBr), v, cm
−1: 745 (C-Cl), 1645 (C=O), 3310 (NH), 3433, 
3352 (NH2). 
General procedure for 5-substituted phenyl-1,3,4-oxadiazol-2-amines (4a,b) 
To the 10 ml methanolic solution of substituted benzohydrazides 3a,b (5 mmol), cyanogen 
bromide (7.5 mmol) was added. The reaction mixture was refluxed on water bath for   
5–7 h. The resulting solution was cooled and neutralized with sodium bicarbonate solution 
(5% w/v). The solid thus separated out was filtered, washed with water, dried and 















Fig. 1.   Numbering of 5-substituted phenyl-1,3,4-oxadiazol-2-amines 4a,b 
5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-amine (4a) 
Yield: 62%, mp: 165–168°C, lit. 164–166°C [32]. IR (KBr), v, cm
−1: 742 (C-Cl), 1265, 1036 
(C-O-C), 1649 (C=N), 3470, 3402 (NH2). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 7.35 (bs, 
2H, NH2), 7.49 (t, J = 7.52 Hz, 1H, H-9), 7.55 (t, J = 7.36 Hz, 1H, H-10), 7.65 (d, J = 7.8 
Hz, 1H, H-8), 7.70 (d, J = 7.48 Hz, 1H, H-11). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 
127.53 (C-10), 128.12 (C-11), 128.69 (C-8), 129.81 (C-9), 131.43 (C-7), 135.18 (C-6), 
157.53 (C-2), 163.50 (C-5). Anal. Calcd. for C8H6N3OCl: C, 49.12; H, 3.09; N, 21.48. 
Found: C, 49.25; H, 3.14; N, 21.41. 
5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-amine (4b) 
Yield: 70%, mp: 243–245°C, lit. 231–233°C [32]. IR (KBr), v, cm
−1: 745 (C-Cl), 1277, 1043 
(C-O-C), 1662 (C=N), 3480, 3396 (NH2). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 7.37 (bs, 
2H, NH2), 7.62 (d, J = 8.24 Hz, 2H, H-8,10), 7.69 (d, J = 8.24 Hz, 2H, H-7,11). 
13C NMR 
(100 MHz, DMSO-d6, TMS): δ 123.34 (C-6), 131.78 (C-7,11), 133.20 (8,10), 135.42 (C-9), 
157.58 (C-2), 163.56 (C-5). Anal. Calcd. for C8H6N3OCl: C, 49.12; H, 3.09; N, 21.48. 
Found: C, 48.98; H, 3.17; N, 21.56. 
General procedure for 4-(5-substitutedphenyl-1,3,4-oxadiazol-2-yl)benzenamines 
(5a,b) 
A mixture of 4-aminobenzoic acid (5 mmol) and substituted benzohydrazides 3a,b 
(5 mmol) in 5 ml phosphorus oxychloride was refluxed on water bath for 7–10 h. After the 
completion of reaction, it was cooled and poured onto crushed ice with continuous stirring. 
The solid mass separated was neutralized with sodium bicarbonate solution (10% w/v). 
The resulting solid thus obtained was collected by filtration, washed well with cold water, 
dried and recrystallized from absolute ethanol. 178  N. B. Patel and J. C. Patel: 


















Fig. 2.   Numbering of 4-(5-substituted phenyl-1,3,4-oxadiazol-2-yl)benzenamines 5a,b 
4-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]benzenamine (5a) 
Yield: 63%, mp: 175–178°C. IR (KBr), v, cm
−1: 746 (C-Cl), 1266, 1042 (C-O-C), 1653 
(C=N), 3482, 3380 (NH2). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 5.46 (bs, 2H, NH2), 6.80 
(d, J = 8.32 Hz, 2H, H-8,10), 7.31 (d, J = 8.32 Hz, 2H, H-7,11), 7.50 (t, J = 7.56 Hz, 1H, H-
15), 7.56 (t, J = 7.4 Hz, 1H, H-16), 7.64 (d, J = 7.84 Hz, 1H, H-14), 7.68 (d, J = 7.5 Hz, 1H, 
H-17). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 108.13 (C-6), 114.84 (C-8,10), 127.53 (C-
16), 128.14 (C-17), 128.62 (C-7,11), 128.74 (C-14), 129.85 (C-15), 131.38 (C-13), 135.22 
(C-12), 148.48 (C-9), 162.37 (C-2,5). Anal. Calcd. for C14H10N3OCl: C, 61.89; H, 3.71; N, 
15.47. Found: C, 61.76; H, 3.75; N, 15.39. 
4-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]benzenamine (5b) 
Yield: 65%, mp: 210–214°C, lit. 210–212°C [12]. IR (KBr), v, cm
−1: 743 (C-Cl), 1268, 1040 
(C-O-C), 1658 (C=N), 3482, 3375 (NH2). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 5.45 (bs, 
2H, NH2), 6.79 (d, J = 8.36 Hz, 2H, H-8,10), 7.29 (d, J = 8.36 Hz, 2H, H-7,11), 7.63 (d, J = 
8.2 Hz, 2H, H-14,16), 7.68 (d, J = 8.2 Hz, 2H, H-13,17). 
13C NMR (100 MHz, DMSO-d6, 
TMS): δ 107.42 (C-6), 114.45 (C-8,10), 123.31 (C-12), 128.73 (C-7,11), 131.82 (C-13,17), 
133.24 (C-14,16), 135.44 (C-15), 148.53 (C-9), 161.89 (C-2,5). Anal. Calcd. for 
C14H10N3OCl: C, 61.89; H, 3.71; N, 15.47. Found: C, 61.78; H, 3.66; N, 15.54. 
General procedure for benzoxazinones (8a–c) 
A mixture of {2-[(2,6-Dichlorophenyl)amino]phenyl}acetyl chloride (6) (10 mmol) and 
substituted anthranilic acids 7a–c (10 mmol) in 20 ml pyridine were stirred at 0–5°C for 
1 h, further stirred for 1 h at room temperature. After completion of reaction, a pasty mass 
obtained, was washed thoroughly with sodium bicarbonate (5 % w/v) to remove unreacted 
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2-[2-(2,6-Dichlorophenyl)amino]benzyl-4H-3,1-benzoxazin-4-one (8aF 
Yield: 53%, mp: 183–186°C, lit. 185–187 °C [33]. IR (KBr), v, cm
−1: 745 (C-Cl), 1151 (C-
O), 1316 (C-N), 1620 (C=N), 1742 (C=O), 2925, 2851 (CH2), 3449 (NH). 
1H NMR (400 
MHz, DMSO-d6, TMS): δ 3.52 (s, 2H, H-11), 6.39 (d, J = 7.96 Hz, 1H, H-14), 6.88 (t, J = 
7.4 Hz, 1H, H-16), 7.04-7.09 (m, 2H, H-15,22), 7.21 (d, J = 7.54 Hz, 1H, H-17), 7.42 (d, J = 
8.08 Hz, 2H, H-21,23), 7.51 (d, J = 8.12 Hz, 1H, H-8), 7.84 (t, J = 7.8 Hz, 1H, H-7), 8.06 (t, 
J = 7.64 Hz, 1H, H-6), 8.12 (d, J = 7.72 Hz, 1H, H-5), 9.12 (bs, 1H, H-18). 
13C NMR (100 
MHz, DMSO-d6, TMS): δ 32.47 (C-11), 116.27 (C-16), 116.54 (C-10), 120.54 (C-14), 
122.35 (C-8), 124.15 (C-22), 126.61 (C-15), 127.12 (C-12), 127.32 (C-21,23), 127.54 (C-
6), 129.34 (C-20,24), 131.23 (C-17), 131.52 (C-5), 135.43 (C-7), 137.23 (C-19), 141.76 (C-
13), 149.53 (C-9), 159.36 (C-4), 164.51 (C-2). Anal. Calcd. for C21H14Cl2N2O2: C, 63.49; H, 
3.55; N, 7.05. Found: C, 63.45; H, 3.56; N, 7.03. 
6-Bromo-2-[2-(2,6-dichlorophenyl)amino]benzyl-4H-3,1-benzoxazin-4-one (8b) 
Yield: 55%, mp: 194–198°C, lit. 193–196 °C. [34]. IR (KBr), v, cm
−1: 565 (C-Br), 743 (C-
Cl), 1153 (C-O), 1318 (C-N), 1618 (C=N), 1740 (C=O), 2926, 2850 (CH2), 3446 (NH). 
1H 
NMR (400 MHz, DMSO-d6, TMS): δ 3.53 (s, 2H, H-11), 6.40 (d, J = 8 Hz, 1H, H-14), 6.88 
(t, J = 7.44 Hz, 1H, H-16), 7.03-7.08 (m, 2H, H-15,22), 7.22 (d, J = 7.58 Hz, 1H, H-17), 
7.41 (d, J = 8.16 Hz, 2H, H-21,23), 7.65 (d, J = 8.32 Hz, 1H, H-8), 8.12 (d, J = 8.32 Hz, 1H, 
H-7), 8.16 (s, 1H, H-5), 9.10 (bs, 1H, H-18). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 32.43 
(C-11), 116.31 (C-16), 118.64 (C-10), 120.62 (C-14), 121.67 (C-6), 124.31 (C-22), 124.57 
(C-8), 126.54 (C-15), 127.17 (C-12), 127.43 (C-21,23), 129.41 (C-20,24), 131.12 (C-17), 
135.22 (C-5), 137.29 (C-19), 138.23 (C-7), 141.78 (C-13), 148.73 (C-9), 159.23 (C-4), 
164.33 (C-2). Anal. Calcd. for C21H13BrCl2N2O2: C, 52.97; H, 2.75; N, 5.88. Found: C, 
52.94; H, 2.74; N, 5.90. 
2-[2-(2,6-Dichlorophenyl)amino]benzyl-6-iodo-4H-3,1-benzoxazin-4-one (8c) 
Yield: 58%, mp: 189–193°C. IR (KBr), v, cm
−1: 620 (C-I), 747 (C-Cl), 1148 (C-O), 1320 (C-
N), 1617 (C=N), 1745 (C=O), 2923, 2848 (CH2), 3450 (NH). 
1H NMR (400 MHz, DMSO-d6, 
TMS): δ 3.53 (s, 2H, H-11), 6.41 (d, J = 7.92 Hz, 1H, H-14), 6.89 (t, J = 7.36 Hz, 1H, H-
16), 7.04-7.09 (m, 2H, H-15,22), 7.22 (d, J = 7.54 Hz, 1H, H-17), 7.25 (d, J = 8.28 Hz, 1H, 
H-8), 7.42 (d, J = 8.12 Hz, 2H, H-21,23), 8.05 (d, J = 8.28 Hz, 1H, H-7), 8.48 (s, 1H, H-5), 
9.10 (bs, 1H, H-18). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 32.53 (C-11), 93.14 (C-6), 
116.25 (C-16), 118.23 (C-10), 120.57 (C-14), 123.74 (C-8), 124.19 (C-22), 126.58 (C-15), 
127.05 (C-12), 127.33 (C-21,23), 129.39 (C-20,24), 131.14 (C-17), 137.42 (C-19), 138.87 
(C-5), 141.81 (C-13), 144.27 (C-7), 148.62 (C-9), 159.53 (C-4), 164.47 (C-2). Anal. Calcd. 
for C21H13Cl2IN2O2: C, 48.21; H, 2.50; N, 5.35. Found: C, 48.25; H, 2.49; N, 5.33. 
General procedure for 1,3,4-oxadiazolyl-quinazolin-4(3H)-ones (9a–f) 
A mixture of benzoxazinones 8a–c (2.5 mmol) and 5-substituted phenyl-1,3,4-oxadiazol-2-
amines  4a,b (2.5 mmol) in 10 ml glacial acetic acid was refluxed under anhydrous 
condition for 4–6 h. After cooling it was poured into crushed ice. The solid separated out 
was filtered, thoroughly washed with cold distilled water, dried, and recrystallized from 
ethanol. 180  N. B. Patel and J. C. Patel: 






































Fig. 4.   Numbering of 1,3,4-Oxadiazolyl-quinazolin-4(3H)-ones 9a–f 
3-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-{2-[(2,6-dichlorophenyl)amino]benzyl}–
quinazolin-4(3H)-one (9a) 
Yield: 63%, mp: 233–235°C. IR (KBr), v, cm
−1: 746 (C-Cl), 1318 (C-N), 1263, 1037 (C-O-C 
oxadiazole), 1609 (C=N quinazolinone), 1650 (C=N oxadiazole), 1678 (C=O 
quinazolinone), 2926, 2853 (CH2), 3445 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.52 
(s, 2H, H-11), 6.41 (d, J = 7.96 Hz, 1H, H-14), 6.89 (t, J = 7.4 Hz, 1H, H-16), 7.03-7.09 (m, 
2H, H-15,22), 7.22 (d, J = 7.54 Hz, 1H, H-17), 7.41 (d, J = 8.08 Hz, 2H, H-21,23), 7.47 (t, J 
= 7.68 Hz, 1H, H-6), 7.50 (t, J = 7.56 Hz, 1H, H-33), 7.57 (t, J = 7.4 Hz, 1H, H-34), 7.61 (d, 
J = 8.16 Hz, 1H, H-8), 7.67 (d, J = 7.84 Hz, 1H, H-32), 7.71 (d, J = 7.52 Hz, 1H, H-35), 
7.76 (t, J = 7.84 Hz, 1H, H-7), 8.10 (d, J = 7.76 Hz, 1H, H-5), 9.09 (bs, 1H, H-18). 
13C NMR 
(100 MHz, DMSO-d6, TMS): δ 32.54 (C-11), 116.32 (C-16), 120.41 (C-14), 120.77 (C-10), 
122.54 (C-8), 124.31 (C-22), 126.54 (C-15), 127.21 (C-12), 127.39 (C-21,23), 127.49 (C-
34), 127.58 (C-6), 128.12 (C-35), 128.55 (C-32), 128.76 (C-5), 129.35 (C-20,24), 129.81 
(C-33), 131.17 (C-17), 131.45 (C-31), 133.66 (C-7), 135.24 (C-30), 137.32 (C-19), 141.68 
(C-13), 147.15 (C-9), 156.72 (C-26), 160.74 (C-4), 163.27 (C-2), 164.65 (C-29). Anal. 
Calcd. for C29H18Cl3N5O2: C, 60.59; H, 3.16; N, 12.18. Found: C, 60.54; H, 3.11; N, 12.21. 
6-Bromo-3-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-{2-[(2,6-dichlorophenyl)amino]–
benzyl}quinazolin-4(3H)-one (9b) 
Yield: 55%, mp: 225–228°C. IR (KBr), v, cm
−1: 570 (C-Br), 745 (C-Cl), 1311 (C-N), 1260, 
1035 (C-O-C oxadiazole), 1611 (C=N quinazolinone), 1653 (C=N oxadiazole), 1675 (C=O 
quinazolinone), 2925, 2851 (CH2), 3447 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.53 
(s, 2H, H-11), 6.39 (d, J = 8 Hz, 1H, H-14), 6.89 (t, J = 7.44 Hz, 1H, H-16), 7.03-7.09 (m, 
2H, H-15,22), 7.21 (d, J = 7.58 Hz, 1H, H-17), 7.42 (d, J = 8.16 Hz, 2H, H-21,23), 7.51 (t, J 
= 7.52 Hz, 1H, H-33), 7.55 (t, J = 7.36 Hz, 1H, H-34), 7.61 (d, J = 8.24 Hz, 1H, H-8), 7.66 
(d, J = 7.8 Hz, 1H, H-32), 7.70 (d, J = 7.48 Hz, 1H, H-35), 8.08 (d, J = 8.24 Hz, 1H, H-7), 
8.12 (s, 1H, H-5), 9.08 (bs, 1H, H-18). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 32.65 (C-
11), 116.24 (C-16), 120.53 (C-14), 123.13 (C-10), 124.24 (C-22), 124.58 (C-8), 126.47 (C-
15), 127.18 (C-12), 127.37 (C-21,23), 127.48 (C-34), 127.66 (C-6), 128.15 (C-35), 128.72 
(C-32), 129.34 (C-20,24), 129.79 (C-33), 131.16 (C-17), 131.47 (C-31), 132.25 (C-5), 
135.21 (C-30), 136.37 (C-7), 137.36 (C-19), 141.77 (C-13), 146.21 (C-9), 156.64 (C-26), 
160.59 (C-4), 163.38 (C-2), 164.57 (C-29). Anal. Calcd. for C29H17BrCl3N5O2: C, 53.28; H, 
2.62; N, 10.71. Found: C, 53.19; H, 2.65; N, 10.75.   Synthesis and Antimicrobial Activity of 3-(1,3,4-Oxadiazol-2-yl)quinazolin-4(3H)-ones 181 
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3-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-{2-[(2,6-dichlorophenyl)amino]benzyl}-
6-iodoquinazolin-4(3H)-one (9c) 
Yield: 66%, mp: 241–244°C. IR (KBr), v, cm
−1: 618 (C-I), 740 (C-Cl), 1317 (C-N), 1262, 
1042 (C-O-C oxadiazole), 1608 (C=N quinazolinone), 1655 (C=N oxadiazole), 1684 (C=O 
quinazolinone), 2928, 2854 (CH2), 3449 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.52 
(s, 2H, H-11), 6.40 (d, J = 7.92 Hz, 1H, H-14), 6.89 (t, J = 7.36 Hz, 1H, H-16), 7.04-7.10 
(m, 2H, H-15,22), 7.21 (d, J = 7.5 Hz, 1H, H-17), 7.25 (d, J = 8.28 Hz, 1H, H-8), 7.41 (d, J 
= 8.12 Hz, 2H, H-21,23), 7.48 (t, J = 7.56 Hz, 1H, H-33), 7.55 (t, J = 7.9 Hz, 1H, H-36), 
7.64 (d, J = 7.84 Hz, 1H, H-32), 7.69 (d, J = 7.48 Hz, 1H, H-35), 7.93 (d, J = 8.28 Hz, 1H, 
H-7), 8.28 (s, 1H, H-5), 9.11 (bs, 1H, H-18). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 32.95 
(C-11), 93.15 (C-6), 116.25 (C-16), 120.44 (C-14), 122.56 (C-10), 124.02 (C-8), 124.23 (C-
22), 126.50 (C-15), 127.13 (C-12), 127.34 (C-21,23), 127.57 (C-34), 128.14 (C-35), 128.71 
(C-32), 129.47 (C-20,24), 129.82 (C-33), 131.30 (C-17), 131.46 (C-31), 135.19 (C-30), 
136.24 (C-5), 137.35 (C-19), 141.78 (C-13), 142.43 (C-7), 146.11 (C-9), 156.69 (C-26), 
160.88 (C-4), 163.35 (C-2), 164.61 (C-29). Anal. Calcd. for C29H17Cl3IN5O2: C, 49.71; H, 
2.45; N, 9.99. Found: C, 49.66; H, 2.51; N, 10.02. 
3-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-{2-[(2,6-dichlorophenyl)amino]benzyl}–
quinazolin-4(3H)-one (9d) 
Yield: 65%, mp: 260–265°C. IR (KBr), v, cm
−1: 748 (C-Cl), 1315 (C-N), 1264, 1038 (C-O-C 
oxadiazole), 1612 (C=N quinazolinone), 1648 (C=N oxadiazole), 1675 (C=O 
quinazolinone), 2923, 2848 (CH2), 3442 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.51 
(s, 2H, H-11), 6.38 (d, J = 8.04 Hz, 1H, H-14), 6.89 (t, J = 7.48 Hz, 1H, H-16), 7.03-7.10 
(m, 2H, H-15,22), 7.22 (d, J = 7.62 Hz, 1H, H-17), 7.43 (d, J = 8.12 Hz, 2H, H-21,23), 7.49 
(t, J = 7.6 Hz, 1H, H-6), 7.61 (d, J = 8.08 Hz, 1H, H-8), 7.65 (d, J = 8.24 Hz, 2H, H-32,34), 
7.70 (d, J = 8.24 Hz, 2H, H-31,35), 7.74 (t, J = 7.8 Hz, 1H, H-7), 8.11 (d, J = 7.72 Hz, 1H, 
H-5), 9.07 (bs, 1H, H-18). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 32.51 (C-11), 116.30 
(C-16), 120.43 (C-14), 120.75 (C-10), 122.52 (C-8), 123.32 (C-30), 124.33 (C-22), 126.57 
(C-15), 127.23 (C-12), 127.41 (C-21,23), 127.60 (C-6), 128.78 (C-5), 129.37 (C-20,24), 
131.20 (C-17), 131.82 (C-31,35), 133.21 (C-32,34), 133.68 (C-7), 135.43 (C-33), 137.36 
(C-19), 141.70 (C-13), 147.17 (C-9), 156.62 (C-26), 160.78 (C-4), 163.37 (C-2), 164.67 (C-




Yield: 61%, mp: 254–258°C. IR (KBr), v, cm
−1: 568 (C-Br), 743 (C-Cl), 1316 (C-N), 1258, 
1032 (C-O-C oxadiazole), 1613 (C=N quinazolinone), 1650 (C=N oxadiazole), 1674 (C=O 
quinazolinone), 2922, 2849 (CH2), 3444 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.52 
(s, 2H, H-11), 6.41 (d, J = 8 Hz, 1H, H-14), 6.90 (t, J = 7.44 Hz, 1H, H-16), 7.04-7.10 (m, 
2H, H-15,22), 7.20 (d, J = 7.58 Hz, 1H, H-17), 7.42 (d, J = 8.08 Hz, 2H, H-21,23), 7.60 (d, 
J = 8.32 Hz, 1H, H-8), 7.64 (d, J = 8.2 Hz, 2H, H-32,34), 7.69 (d, J =8.2 Hz, 2H, H-31,35), 
8.01 (d, J = 8.32 Hz, 1H, H-7), 8.09 (s, 1H, H-5), 9.08 (bs, 1H, H-18). 
13C NMR (100 MHz, 
DMSO-d6, TMS): δ 32.57 (C-11), 116.28 (C-16), 120.56 (C-14), 123.16 (C-10), 123.33 (C-
30), 124.27 (C-22), 124.56 (C-8), 126.48 (C-15), 127.22 (C-12), 127.39 (C-21,23), 127.67 
(C-6), 129.35 (C-20,24), 131.18 (C-17), 131.79 (C-31,35), 132.24 (C-5), 133.24 (C-32,34), 
135.39 (C-33), 136.35 (C-7), 137.38 (C-19), 141.76 (C-13), 146.23 (C-9), 156.58 (C-26), 182  N. B. Patel and J. C. Patel: 
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160.61 (C-4), 163.41 (C-2), 164.54 (C-29). Anal. Calcd. for C29H17BrCl3N5O2: C, 53.28; H, 
2.62; N, 10.71. Found: C, 53.35; H, 2.66; N, 10.58. 
3-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-{2-[(2,6-dichlorophenyl)amino]benzyl}-
6-iodoquinazolin-4(3H)-one (9f) 
Yield: 68%, mp: 273–277°C. IR (KBr), v, cm
−1: 615 (C-I), 746 (C-Cl), 1315 (C-N), 1260, 
1045 (C-O-C oxadiazole), 1612 (C=N quinazolinone), 1651 (C=N oxadiazole), 1680 (C=O 
quinazolinone), 2927, 2852 (CH2), 3450 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.51 
(s, 2H, H-11), 6.41 (d, J = 7.92 Hz, 1H, H-14), 6.88 (t, J = 7.36 Hz, 1H, H-16), 7.05-7.08 
(m, 2H, H-15,22), 7.21 (d, J = 7.54 Hz, 1H, H-17), 7.25 (d, J = 8.36 Hz, 1H, H-8), 7.41 (d, J 
= 8.12 Hz, 2H, H-21,23), 7.62 (d, J = 8.28 Hz, 2H, H-32,34), 7.68 (d, J = 8.28 Hz, 2H, H-
31,35), 7.95 (d, J = 8.36 Hz, 1H, H-7), 8.28 (s, 1H, H-5), 9.11 (bs, 1H, H-18). 
13C NMR 
(100 MHz, DMSO-d6, TMS): δ 33.05 (C-11), 93.18 (C-6), 116.29 (C-16), 120.42 (C-14), 
122.58 (C-10), 123.30 (C-30), 124.08 (C-8), 124.25 (C-22), 126.52 (C-15), 127.16 (C-12), 
127.35 (C-21,23), 129.46 (C-20,24), 131.32 (C-17), 131.77 (C-31,35), 133.25 (C-32,34), 
135.41 (C-33), 136.23 (C-5), 137.34 (C-19), 141.76 (C-13), 142.45 (C-7), 146.13 (C-9), 
156.65 (C-26), 160.89 (C-4), 163.37 (C-2), 164.62 (C-29). Anal. Calcd. for C29H17Cl3IN5O2: 
C, 49.71; H, 2.45; N, 9.99. Found: C, 49.65; H, 2.47; N, 10.04. 
General procedure for 1,3,4-oxadiazolyl-quinazolin-4(3H)-ones (10a-f) 
A mixture of benzoxazinones 8a–c (2.5 mmol) and 4-(5-substituted phenyl-1,3,4-
oxadiazol-2-yl)benzenamines 5a,b (2.5 mmol) 10 ml in pyridine was refluxed on an oil bath 
for 6-8 h. After completion of the reaction, the oily mass was slowly poured onto crushed 
ice cold water containing 5 ml concentrated HCl with continues stirring. The product 












































Fig. 5.   Numbering of 1,3,4-Oxadiazolyl-quinazolin-4(3H)-ones 10a–f 
3-{4-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]phenyl}-2-{2-[(2,6-dichlorophenyl)amino]–
benzyl}quinazolin-4(3H)-one (10a) 
Yield: 62%, mp: 228–231°C. IR (KBr), v, cm
−1: 740 (C-Cl), 1316 (C-N), 1265, 1041 (C-O-C 
oxadiazole), 1610 (C=N quinazolinone), 1656 (C=N oxadiazole), 1676 (C=O 
quinazolinone), 2925, 2852 (CH2), 3446 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.51 
(s, 2H, H-11), 6.40 (d, J = 8 Hz, 1H, H-14), 6.89 (t, J = 7.4 Hz, 1H, H-16), 7.03-7.09 (m,   Synthesis and Antimicrobial Activity of 3-(1,3,4-Oxadiazol-2-yl)quinazolin-4(3H)-ones 183 
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2H, H-15,22), 7.22 (d, J = 7.58 Hz, 1H, H-17), 7.42 (d, J = 8.16 Hz, 2H, H-21,23), 7.45 (d, 
J = 8.4 Hz, 2H, H-26,30), 7.47-7.55 (m, 4H, Ar-H), 7.57 (t, J = 7.36 Hz, 1H, H-40), 7.62 (d, 
J = 8.16 Hz, 1H, H-8), 7.66 (d, J = 7.8 Hz, 1H, H-38), 7.71 (d, J = 7.48 Hz, 1H, H-41), 7.75 
(t, J = 7.84 Hz, 1H, H-7), 8.07 (d, J = 7.74 Hz, 1H, H-5), 9.11 (bs, 1H, H-18). 
13C NMR (100 
MHz, DMSO-d6, TMS): δ 32.48 (C-11), 116.27 (C-16), 120.43 (C-14), 120.81 (C-10), 
121.47 (C-28), 121.82 (C-26,30), 122.58 (C-8), 124.34 (C-22), 126.57 (C-15), 127.23 (C-
12), 127.40 (C-21,23), 127.51 (C-40), 127.61 (C-6), 127.72 (C-27,29), 128.14 (C-41), 
128.67 (C-38), 128.78 (C-5), 129.33 (C-20,24), 129.78 (C-39), 131.18 (C-17), 131.43 (C-
37), 132.64 (C-25), 133.62 (C-7), 135.22 (C-36), 137.34 (C-19), 141.67 (C-13), 147.12 (C-
9), 160.73 (C-4), 163.26 (C-2), 164.64 (C-32, 35). Anal. Calcd. for C35H22Cl3N5O2: C, 
64.58; H, 3.41; N, 10.76. Found: C, 64.51; H, 3.46; N, 10.71. 
6-Bromo-3-{4-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]phenyl}-2-{2-[(2,6-dichlorophenyl)–
amino]benzyl}quinazolin-4(3H)-one (10b) 
Yield: 64%, mp: 213–217°C. IR (KBr), v, cm
−1: 572 (C-Br), 743 (C-Cl), 1312 (C-N), 1268, 
1048 (C-O-C oxadiazole), 1609 (C=N quinazolinone), 1653 (C=N oxadiazole), 1681 (C=O 
quinazolinone), 2921, 2847 (CH2), 3442 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.53 
(s, 2H, H-11), 6.42 (d, J = 7.96 Hz, 1H, H-14), 6.91 (t, J = 7.44 Hz, 1H, H-16), 7.03-7.10 
(m, 2H, H-15,22), 7.23 (d, J = 7.58 Hz, 1H, H-17), 7.42 (d, J = 8.12 Hz, 2H, H-21,23), 7.45 
(d, J = 8.36 Hz, 2H, H-26,30), 7.48 (t, J = 7.56 Hz, 1H, H-39), 7.54 (t, J = 7.4 Hz, 1H, H-
40), 7.57 (d, J = 8.36 Hz, 2H, H-27,29), 7.61 (d, J = 8.4 Hz, 1H, H-8), 7.65 (d, J = 7.8 Hz, 
1H, H-38), 7.72 (d, J = 7.48 Hz, 1H, H-41), 8.05 (d, J = 8.4 Hz, 1H, H-7), 8.12 (s, 1H, H-5), 
9.11 (bs, 1H, H-18). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 32.63 (C-11), 116.27 (C-16), 
120.55 (C-14), 121.52 (C-28), 121.78 (C-26,30), 123.12 (C-10), 124.26 (C-22), 124.62 (C-
8), 126.50 (C-15), 127.17 (C-12), 127.38 (C-21,23), 127.53 (C-40), 127.64 (C-6), 127.73 
(C-27,29), 128.17 (C-41), 128.76 (C-38), 129.37 (C-20,24), 129.82 (C-39), 131.20 (C-17), 
131.45 (C-37), 132.27 (C-5), 132.64 (C-25), 135.23 (C-36), 136.35 (C-7), 137.32 (C-19), 
141.74 (C-13), 146.23 (C-9), 160.60 (C-4), 163.28 (C-2), 164.59 (C-32,35). Anal. Calcd. 
for C35H21BrCl3N5O2: C, 57.60; H, 2.90; N, 9.60. Found: C, 57.52; H, 2.94; N, 9.63. 
3-{4-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]phenyl}-2-{2-[(2,6-dichlorophenyl)amino]–
benzyl}-6-iodoquinazolin-4(3H)-one (10c) 
Yield: 60%, mp: 235–238°C. IR (KBr), v, cm
−1: 620 (C-I), 748 (C-Cl), 1312 (C-N), 1270, 
1051 (C-O-C oxadiazole), 1611 (C=N quinazolinone), 1649 (C=N oxadiazole), 1678 (C=O 
quinazolinone), 2928, 2855 (CH2), 3448 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.52 
(s, 2H, H-11), 6.41 (d, J = 8 Hz, 1H, H-14), 6.88 (t, J = 7.44 Hz, 1H, H-16), 7.05-7.11 (m, 
2H, H-15,22), 7.23 (d, J = 7.54 Hz, 1H, H-17), 7.26 (d, J = 8.32 Hz, 1H, H-8), 7.43 (d, J = 
8.04 Hz, 2H, H-21,23), 7.46 (d, J = 8.44 Hz, 2H, H-26,30), 7.49 (t, J = 7.6 Hz, 1H, H-39), 
7.53 (d, J = 8.44 Hz, 2H, H-27,29), 7.56 (t, J = 7.42 Hz, 1H, H-40), 7.63 (d, J = 7.88 Hz, 
1H, H-38), 7.69 (d, J = 7.56 Hz, 1H, H-41), 7.93 (d, J = 8.32 Hz, 1H, H-7), 8.28 (s, 1H, H-
5), 9.09 (bs, 1H, H-18). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 32.90 (C-11), 93.21 (C-6), 
116.29 (C-16), 120.48 (C-14), 121.49 (C-28), 121.81 (C-26,30), 122.55 (C-10), 124.05 (C-
8), 124.25 (C-22), 126.49 (C-15), 127.15 (C-12), 127.38 (C-21,23), 127.49 (C-40), 127.68 
(C-27,29), 128.12 (C-41), 128.68 (C-38), 129.44 (C-20,24), 129.74 (C-39), 131.29 (C-17), 
131.40 (C-37), 132.58 (C-25), 135.18 (C-36), 136.21 (C-5), 137.37 (C-19), 141.75 (C-13), 
142.46 (C-7), 146.09 (C-9), 160.95 (C-4), 163.22 (C-2), 164.63 (C-32,35). Anal. Calcd. for 
C35H21Cl3IN5O2: C, 54.11; H, 2.72; N, 9.02. Found: C, 54.18; H, 2.76; N, 8.95. 184  N. B. Patel and J. C. Patel: 
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3-{4-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]phenyl}-2-{2-[(2,6-dichlorophenyl)amino]–
benzyl}quinazolin-4(3H)-one (10d) 
Yield: 59%, mp: 245–248°C. IR (KBr), v, cm
−1: 748 (C-Cl), 1318 (C-N), 1275, 1045 (C-O-C 
oxadiazole), 1613 (C=N quinazolinone), 1658 (C=N oxadiazole), 1680 (C=O 
quinazolinone), 2925, 2852 (CH2), 3451 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.52 
(s, 2H, H-11), 6.40 (d, J = 7.88 Hz, 1H, H-14), 6.89 (t, J = 7.36 Hz, 1H, H-16), 7.04-7.09 
(m, 2H, H-15,22), 7.21 (d, J = 7.5 Hz, 1H, H-17), 7.42 (d, J = 8.08 Hz, 2H, H-21,23), 7.45 
(d, J = 8.36 Hz, 2H, H-26,30), 7.49 (t, J = 7.6 Hz, 1H, H-6), 7.56 (d, J = 8.36 Hz, 2H, H-
27,29), 7.61 (d, J = 8.12 Hz, 1H, H-8), 7.65 (d, J = 8.28 Hz, 2H, H-37,41), 7.68 (d, J = 8.28 
Hz, 2H, H-38,40), 7.75 (t, J = 7.8 Hz, 1H, H-7), 8.09 (d, J = 7.68 Hz, 1H, H-5), 9.10 (bs, 
1H, H-18). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 32.61 (C-11), 116.30 (C-16), 120.45 
(C-14), 120.75 (C-10), 121.52 (C-28), 121.78 (C-26,30), 122.57 (C-8), 123.28 (C-36), 
124.32 (C-22), 126.51 (C-15), 127.19 (C-12), 127.37 (C-21,23), 127.56 (C-6), 127.68 (C-
27,29), 128.74 (C-5), 129.32 (C-20,24), 131.15 (C-17), 131.83 (C-37,41), 132.59 (C-25), 
133.19 (C-38,40), 133.64 (C-7), 135.42 (C-39), 137.34 (C-19), 141.65 (C-13), 147.13 (C-
9), 160.77 (C-4), 163.38 (C-2), 164.61 (C-32,35). Anal. Calcd. for C35H22Cl3N5O2: C, 64.58; 
H, 3.41; N, 10.76. Found: C, 64.53; H, 3.44; N, 10.73. 
6-Bromo-3-{4-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]phenyl}-2-{2-[(2,6-dichlorophenyl)–
amino]benzyl}quinazolin-4(3H)-one (10e) 
Yield: 68%, mp: 221–224°C. IR (KBr), v, cm
−1: 565 (C-Br), 747 (C-Cl), 1317 (C-N), 1266, 
1044 (C-O-C oxadiazole), 1609 (C=N quinazolinone), 1650 (C=N oxadiazole), 1676 (C=O 
quinazolinone), 2923, 2852 (CH2), 3446 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.53 
(s, 2H, H-11), 6.41 (d, J = 7.96 Hz, 1H, H-14), 6.90 (t, J = 7.4 Hz, 1H, H-16), 7.04-7.10 (m, 
2H, H-15,22), 7.20 (d, J = 7.58 Hz, 1H, H-17), 7.42 (d, J = 8.12 Hz, 2H, H-21,23), 7.46 (d, 
J = 8.4 Hz, 2H, H-26,30), 7.56 (d, J = 8.4 Hz, 2H, H-27,29), 7.60 (d, J = 8.28 Hz, 1H, H-8), 
7.64 (d, J = 8.24 Hz, 2H, H-38,40), 7.69 (d, J = 8.24 Hz, 2H, H-37,41), 8.07 (d, J = 8.28 
Hz, 1H, H-7), 8.13 (s, 1H, H-5), 9.11 (bs, 1H, H-18). 
13C NMR (100 MHz, DMSO-d6, TMS): 
δ 32.67 (C-11), 116.25 (C-16), 120.56 (C-14), 121.53 (C-28), 121.79 (C-26,30), 123.16 (C-
10), 123.32 (C-36), 124.27 (C-22), 124.56 (C-8), 126.44 (C-15), 127.15 (C-12), 127.34 (C-
21,23), 127.62 (C-6), 127.74 (C-27,29), 129.38 (C-20,24), 131.22 (C-17), 131.82 (C-
37,41), 132.28 (C-5), 132.62 (C-25), 133.22 (C-38,40), 135.41 (C-39), 136.35 (C-7), 
137.32 (C-19), 141.73 (C-13), 146.25 (C-9), 160.56 (C-4), 163.37 (C-2), 164.52 (C-32,35). 




Yield: 65%, mp: 257–261°C. IR (KBr), v, cm
−1: 617 (C-I), 745 (C-Cl), 1314 (C-N), 1268, 
1052 (C-O-C oxadiazole), 1608 (C=N quinazolinone), 1652 (C=N oxadiazole), 1679 (C=O 
quinazolinone), 2925, 2851 (CH2), 3443 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.51 
(s, 2H, H-11), 6.39 (d, J = 8 Hz, 1H, H-14), 6.88 (t, J = 7.48 Hz, 1H, H-16), 7.03-7.10 (m, 
2H, H-15,22), 7.20 (d, J = 7.58 Hz, 1H, H-17), 7.24 (d, J = 8.24 Hz, 1H, H-8), 7.43 (d, J = 
8.16 Hz, 2H, H-21,23), 7.47 (d, J = 8.32 Hz, 2H, H-26,30), 7.58 (d, J = 8.32 Hz, 2H, H-
27,29), 7.63 (d, J = 8.2 Hz, 2H, H-38,40), 7.68 (d, J = 8.2 Hz, 2H, H-37,41), 7.95 (d, J = 
8.24 Hz, 1H, H-7), 8.28 (s, 1H, H-5), 9.12 (bs, 1H, H-18). 
13C NMR (100 MHz, DMSO-d6, 
TMS): δ 33.01 (C-11), 93.20 (C-6), 116.21 (C-16), 120.43 (C-14), 121.48 (C-28), 121.76   Synthesis and Antimicrobial Activity of 3-(1,3,4-Oxadiazol-2-yl)quinazolin-4(3H)-ones 185 
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(C-26,30), 122.55 (C-10), 123.34 (C-36), 124.06 (C-8), 124.25 (C-22), 126.48 (C-15), 
127.14 (C-12), 127.32 (C-21,23), 127.67 (C-27,29), 129.43 (C-20,24), 131.33 (C-17), 
131.82 (C-37,41), 132.63 (C-25), 133.23 (C-38,40), 135.44 (C-39), 136.28 (C-5), 137.34 
(C-19), 141.76 (C-13), 142.48 (C-7), 146.15 (C-9), 160.93 (C-4), 163.31 (C-2), 164.59 (C-
32,35). Anal. Calcd. for C35H21Cl3IN5O2: C, 54.11; H, 2.72; N, 9.02. Found: C, 54.06; H, 
2.75; N, 9.09. 
General procedure for quinazolin-4(3H)-ones (11a–c)  
A mixture of benzoxazinones 8a–c (5 mmol) and glycine (5 mmol) was refluxed in 20 ml 
butanol for 6-8 h. After completion of the reaction, it was concentrated and after cooling, 
































Fig. 6.   Numbering of Quinazolin-4(3H)-ones 11a–c 
[2-{2-[(2,6-Dichlorophenyl)amino]benzyl}-4-oxoquinazolin-3(4H)-yl]acetic acid (11a) 
Yield: 53%, mp: 202–206°C. IR (KBr), v, cm
−1: 741 (C-Cl), 1315 (C-N), 1608 (C=N 
quinazolinone), 1686 (C=O quinazolinone), 1715 (C=O), 2780 (OH), 2924, 2851 (CH2), 
3447 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.52 (s, 2H, H-11), 4.15 (s, 2H, H-25), 
6.39 (d, J = 7.96 Hz, 1H, H-14), 6.88 (t, J = 7.44 Hz, 1H, H-16), 7.04-7.09 (m, 2H, H-
15,22), 7.21 (d, J = 7.58 Hz, 1H, H-17), 7.42 (d, J = 8.08 Hz, 2H, H-21,23), 7.48 (t, J = 
7.72 Hz, 1H, H-6), 7.62 (d, J = 8.2 Hz, 1H, H-8), 7.75 (t, J = 7.88 Hz, 1H, H-7), 8.10 (d, J = 
7.8 Hz, 1H, H-5), 9.10 (bs, 1H, H-18), 12.34 (bs, 1H, H-26). 
13C NMR (100 MHz, DMSO-
d6, TMS): δ 32.62 (C-11), 42.93 (C-25), 116.31 (C-16), 120.44 (C-14), 120.91 (C-10), 
122.52 (C-8), 124.29 (C-22), 126.51 (C-15), 127.18 (C-12), 127.37 (C-21,23), 127.82 (C-
6), 128.71 (C-5), 129.32 (C-20,24), 131.14 (C-17), 135.74 (C-7), 137.28 (C-19), 141.71 (C-
13), 147.13 (C-9), 160.72 (C-4), 164.63 (C-2), 173.52 (C-26). Anal. Calcd. for 
C23H17Cl2N3O3: C, 60.81; H, 3.77; N, 9.25. Found: C, 60.75; H, 3.70; N, 9.28. 
[6-Bromo-2-{2-[(2,6-dichlorophenyl)amino]benzyl}-4-oxoquinazolin-3(4H)-yl]acetic acid 
(11b) 
Yield: 56%, mp: 223–227°C. IR (KBr), v, cm
−1: 567 (C-Br), 744 (C-Cl), 1317 (C-N), 1610 
(C=N quinazolinone), 1684 (C=O quinazolinone), 1718 (C=O), 2785 (OH), 2925, 2849 
(CH2), 3445 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.53 (s, 2H, H-11), 4.14 (s, 2H, 
H-25), 6.40 (d, J = 8 Hz, 1H, H-14), 6.88 (t, J = 7.4 Hz, 1H, H-16), 7.03-7.08 (m, 2H, H-
15,22), 7.22 (d, J = 7.5 Hz, 1H, H-17), 7.41 (d, J = 8.12 Hz, 2H, H-21,23), 7.63 (d, J = 8.36 186  N. B. Patel and J. C. Patel: 
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Hz, 1H, H-8), 7.95 (d, J = 8.36 Hz, 1H, H-7), 8.03 (s, 1H, H-5), 9.09 (bs, 1H, H-18), 12.35 
(bs, 1H, H-26). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 32.73 (C-11), 43.32 (C-25), 116.28 
(C-16), 120.57 (C-14), 121.65 (C-6), 122.94 (C-10), 124.19 (C-22), 124.51 (C-8), 126.42 
(C-15), 127.15 (C-12), 127.38 (C-21,23), 129.31 (C-20,24), 131.22 (C-17), 132.14 (C-5), 
137.37 (C-19), 138.33 (C-7), 141.81 (C-13), 145.83 (C-9), 160.93 (C-4), 164.55 (C-2), 
173.47 (C-26). Anal. Calcd. for C23H16BrCl2N3O3: C, 51.81; H, 3.02; N, 7.88. Found: C, 
51.85; H, 3.05; N, 7.84. 
[2-{2-[(2,6-Dichlorophenyl)amino]benzyl}-6-iodo-4-oxoquinazolin-3(4H)-yl]acetic acid (11c) 
Yield: 60%, mp: 211–214°C. IR (KBr), v, cm
−1: 618 (C-I), 746 (C-Cl), 1318 (C-N), 1612 
(C=N quinazolinone), 1682 (C=O quinazolinone), 1713 (C=O), 2778 (OH), 2922, 2846 
(CH2), 3443 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.53 (s, 2H, H-11), 4.16 (s, 2H, 
H-25), 6.41 (d, J = 7.92 Hz, 1H, H-14), 6.89 (t, J = 7.36 Hz, 1H, H-16), 7.04-7.09 (m, 2H, 
H-15,22), 7.22 (d, J = 7.5 Hz, 1H, H-17), 7.26 (d, J = 8.32 Hz, 1H, H-8), 7.42 (d, J = 8.04 
Hz, 2H, H-21,23), 7.94 (d, J = 8.32 Hz, 1H, H-7), 8.27 (s, 1H, H-5), 9.09 (bs, 1H, H-18), 
12.35 (bs, 1H, H-26). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 33.12 (C-11), 43.26 (C-25), 
93.32 (C-6), 116.26 (C-16), 120.51 (C-14), 122.52 (C-10), 123.92 (C-8), 124.13 (C-22), 
126.58 (C-15), 126.98 (C-12), 127.26 (C-21,23), 129.32 (C-20,24), 131.24 (C-17), 136.14 
(C-5), 137.28 (C-19), 141.67 (C-13), 142.45 (C-7), 145.74 (C-9), 161.16 (C-4), 164.62 (C-
2), 173.44 (C-26). Anal. Calcd. for C23H16Cl2IN3O3: C, 47.61; H, 2.78; N, 7.24. Found: C, 
47.57; H, 2.75; N, 7.25. 
General procedure for 1,3,4-oxadiazolyl-quinazolin-4(3H)-ones (12a–f) 
A mixture of 11a–c (2.5 mmol), benzohydrazides 3a,b (2.5 mmol) and 7 ml phosphorus 
trichloride in 10 ml dry benzene was refluxed under anhydrous condition for 10-12 h. After 
completion of reaction, benzene was distilled off under reduced pressure and the residue 
poured on to crushed ice and neutralized with sodium bicarbonate (5% w/v). The solid thus 










































Fig. 7.   Numbering of 1,3,4-Oxadiazolyl-quinazolin-4(3H)-ones 12a–f 
3-{[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]methyl}-2-{2-[(2,6-dichlorophenyl)amino]-
benzyl}quinazolin-4(3H)-one (12a)  
Yield: 72%, mp: 181–184°C. IR (KBr), v, cm
−1: 744 (C-Cl), 1313 (C-N), 1259, 1035 (C-O-C 
oxadiazole), 1611 (C=N quinazolinone), 1653 (C=N oxadiazole), 1678 (C=O   Synthesis and Antimicrobial Activity of 3-(1,3,4-Oxadiazol-2-yl)quinazolin-4(3H)-ones 187 
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quinazolinone), 2923, 2855 (CH2), 3448 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.51 
(s, 2H, H-11), 4.49 (s, 2H, H-25), 6.40 (d, J = 7.96 Hz, 1H, H-14), 6.89 (t, J = 7.44 Hz, 1H, 
H-16), 7.05-7.10 (m, 2H, H-15,22), 7.22 (d, J = 7.58 Hz, 1H, H-17), 7.42 (d, J = 8.12 Hz, 
2H, H-21,23), 7.47 (t, J = 7.56 Hz, 1H, H-34), 7.51 (t, J = 7.64 Hz, 1H, H-6), 7.56 (t, J = 7.4 
Hz, 1H, H-35), 7.61 (d, J = 8.12 Hz, 1H, H-8), 7.67 (d, J = 7.84 Hz, 1H, H-33), 7.71 (d, J = 
7.48 Hz, 1H, H-36), 7.75 (t, J = 7.8 Hz, 1H, H-7), 8.09 (d, J = 7.72 Hz, 1H, H-5), 9.10 (bs, 
1H, H-18). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 33.02 (C-11), 42.42 (C-25), 116.32 (C-
16), 120.45 (C-14), 120.93 (C-10), 122.57 (C-8), 124.31 (C-22), 126.54 (C-15), 127.22 (C-
12), 127.39 (C-21,23), 127.61 (C-35), 127.83 (C-6), 128.24 (C-36), 128.73 (C-5), 128.82 
(C-33), 129.37 (C-20,24), 129.75 (C-34), 131.18 (C-17), 131.79 (C-32), 135.47 (C-31), 
135.81 (C-7), 137.34 (C-19), 141.75 (C-13), 147.18 (C-9), 156.28 (C-27), 160.74 (C-4), 
163.46 (C-2), 164.65 (C-30). Anal. Calcd. for C30H20Cl3N5O2: C, 61.19; H, 3.42; N, 11.89. 
Found: C, 61.12; H, 3.47; N, 11.85. 
6-Bromo-3-{[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]methyl}-2-{2-[(2,6-dichlorophenyl)-
amino]benzyl}quinazolin-4(3H)-one (12b) 
Yield: 68%, mp: 175–178°C. IR (KBr), v, cm
−1: 568 (C-Br), 742 (C-Cl), 1311 (C-N), 1263, 
1045 (C-O-C oxadiazole), 1612 (C=N quinazolinone), 1653 (C=N oxadiazole), 1675 (C=O 
quinazolinone), 2922, 2850 (CH2), 3443 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.53 
(s, 2H, H-11), 4.48 (s, 2H, H-25), 6.40 (d, J = 8 Hz, 1H, H-14), 6.88 (t, J = 7.48 Hz, 1H, H-
16), 7.03-7.08 (m, 2H, H-15,22), 7.22 (d, J = 7.58 Hz, 1H, H-17), 7.41 (d, J = 8.08 Hz, 2H, 
H-21,23), 7.49 (t, J = 7.52 Hz, 1H, H-34), 7.56 (t, J = 7.36 Hz, 1H, H-35), 7.62 (d, J = 8.28 
Hz, 1H, H-8), 7.67 (d, J = 7.8 Hz, 1H, H-33), 7.72 (d, J = 7.48 Hz, 1H, H-36), 8.06 (d, J = 
8.28 Hz, 1H, H-7), 8.11 (s, 1H, H-5), 9.10 (bs, 1H, H-18). 
13C NMR (100 MHz, DMSO-d6, 
TMS): δ 33.14 (C-11), 42.47 (C-25), 116.32 (C-16), 120.63 (C-14), 121.68 (C-6), 122.96 
(C-10), 124.22 (C-22), 124.54 (C-8), 126.46 (C-15), 127.17 (C-12), 127.42 (C-21,23), 
127.67 (C-35), 128.26 (C-36), 128.72 (C-33), 129.35 (C-20,24), 129.69 (C-34), 131.24 (C-
17), 131.84 (C-32), 132.16 (C-5), 135.52 (C-31), 137.43 (C-19), 138.37 (C-7), 141.84 (C-
13), 145.85 (C-9), 156.25 (C-27), 160.97 (C-4), 163.41 (C-2), 164.56 (C-30). Anal. Calcd. 
for C30H19BrCl3N5O2: C, 53.96; H, 2.87; N, 10.49. Found: C, 53.88; H, 2.85; N, 10.53. 
3-{[5-(2-Clorophenyl)-1,3,4-oxadiazol-2-yl]methyl}-2-{2-[(2,6-dichlorophenyl)amino]benzyl}-
6-iodoquinazolin-4(3H)-one (12c) 
Yield: 62%, mp: 196–98°C. IR (KBr), v, cm
−1: 620 (C-I), 745 (C-Cl), 1316 (C-N), 1265, 
1036 (C-O-C oxadiazole), 1609 (C=N quinazolinone), 1650 (C=N oxadiazole), 1678 (C=O 
quinazolinone), 2924, 2850 (CH2), 3445 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.53 
(s, 2H, H-11), 4.48 (s, 2H, H-25), 6.41 (d, J = 8 Hz, 1H, H-14), 6.89 (t, J = 7.48 Hz, 1H, H-
16), 7.04-7.09 (m, 2H, H-15,22), 7.22 (d, J = 7.62 Hz, 1H, H-17), 7.26 (d, J = 8.36 Hz, 1H, 
H-8), 7.42 (d, J = 8.12 Hz, 2H, H-21,23), 7.50 (t, J = 7.52 Hz, 1H, H-34), 7.56 (t, J = 7.36 
Hz, 1H, H-35), 7.65 (d, J = 7.8 Hz, 1H, H-33), 7.71 (d, J = 7.44 Hz, 1H, H-36), 7.94 (d, J = 
8.36 Hz, 1H, H-7), 8.27 (s, 1H, H-5), 9.09 (bs, 1H, H-18). 
13C NMR (100 MHz, DMSO-d6, 
TMS): δ 33.51 (C-11), 42.47 (C-25), 93.33 (C-6), 116.27 (C-16), 120.53 (C-14), 122.55 (C-
10), 123.91 (C-8), 124.16 (C-22), 126.62 (C-15), 127.11 (C-12), 127.28 (C-21,23), 127.64 
(C-35), 128.26 (C-36), 128.73 (C-33), 129.37 (C-20,24), 129.75 (C-34), 131.28 (C-17), 
131.84 (C-32), 136.15 (C-5), 135.52 (C-31), 137.31 (C-19), 141.70 (C-13), 142.48 (C-7), 
145.77 (C-9), 156.23 (C-27), 161.18 (C-4), 163.44 (C-2), 164.67 (C-30). Anal. Calcd. for 
C30H19Cl3IN5O2: C, 50.41; H, 2.68; N, 9.80. Found: C, 50.45; H, 2.71; N, 9.73. 188  N. B. Patel and J. C. Patel: 
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3-{[5-(4Chlorophenyl)-1,3,4-oxadiazol-2-yl]methyl}-2-{2-[(2,6-dichlorophenyl)amino]-
benzyl}quinazolin-4(3H)-one (12d) 
Yield: 71%, mp: 227–30°C. IR (KBr), v, cm
−1: 748 (C-Cl), 1316 (C-N), 1254, 1038 (C-O-C 
oxadiazole), 1608 (C=N quinazolinone), 1655 (C=N oxadiazole), 1683 (C=O 
quinazolinone), 2922, 2851 (CH2), 3443 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.52 
(s, 2H, H-11), 4.47 (s, 2H, H-25), 6.39 (d, J = 8.04 Hz, 1H, H-14), 6.88 (t, J = 7.52 Hz, 1H, 
H-16), 7.04-7.09 (m, 2H, H-15,22), 7.21 (d, J = 7.62 Hz, 1H, H-17), 7.42 (d, J = 8.16 Hz, 
2H, H-21,23), 7.50 (t, J = 7.68 Hz, 1H, H-6), 7.62 (d, J = 8.16 Hz, 1H, H-8), 7.65 (d, J = 8.2 
Hz, 2H, H-33,35), 7.70 (d, J = 8.2 Hz, 2H, H-32,36), 7.74 (t, J = 7.84 Hz, 1H, H-7), 8.08 (d, 
J = 7.76 Hz, 1H, H-5), 9.12 (bs, 1H, H-18). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 33.05 
(C-11), 42.23 (C-25), 116.35 (C-16), 120.48 (C-14), 120.96 (C-10), 122.55 (C-8), 123.34 
(C-31), 124.34 (C-22), 126.53 (C-15), 127.26 (C-12), 127.34 (C-21,23), 127.77 (C-6), 
128.74 (C-5), 129.35 (C-20,24), 131.21 (C-17), 131.83 (C-32,36), 133.26 (C-33,35), 
135.38 (C-34), 135.78 (C-7), 137.36 (C-19), 141.76 (C-13), 147.18 (C-9), 156.27 (C-27), 
160.78 (C-4), 163.38 (C-2), 164.67 (C-30). Anal. Calcd. for C30H20Cl3N5O2: C, 61.19; H, 
3.42; N, 11.89. Found: C, 61.22; H, 3.38; N, 11.84. 
6-Bromo-3-{[5-(4chlorophenyl)-1,3,4-oxadiazol-2-yl]methyl}-2-{2-[(2,6-dichlorophenyl)-
amino]benzyl}quinazolin-4(3H)-one (12e) 
Yield: 67%, mp: 266–69°C. IR (KBr), v, cm
−1: 571 (C-Br), 750 (C-Cl), 1313 (C-N), 1263, 
1041 (C-O-C oxadiazole), 1607 (C=N quinazolinone), 1656 (C=N oxadiazole), 1678 (C=O 
quinazolinone), 2925, 2853 (CH2), 3448 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.53 
(s, 2H, H-11), 4.49 (s, 2H, H-25), 6.40 (d, J = 7.88 Hz, 1H, H-14), 6.89 (t, J = 7.32 Hz, 1H, 
H-16), 7.02-7.08 (m, 2H, H-15,22), 7.20 (d, J = 7.46 Hz, 1H, H-17), 7.42 (d, J = 8.04 Hz, 
2H, H-21,23), 7.60 (d, J = 8.32 Hz, 1H, H-8), 7.65 (d, J = 8.24 Hz, 2H, H-33,35), 7.72 (d, J 
= 8.24 Hz, 2H, H-32,36), 8.05 (d, J = 8.32 Hz, 1H, H-7), 8.12 (s, 1H, H-5), 9.08 (bs, 1H, H-
18). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 33.15 (C-11), 42.51 (C-25), 116.25 (C-16), 
120.54 (C-14), 121.63 (C-6), 122.87 (C-10), 123.30 (C-31), 124.15 (C-22), 124.46 (C-8), 
126.38 (C-15), 127.17 (C-12), 127.42 (C-21,23), 129.28 (C-20,24), 131.25 (C-17), 131.78 
(C-32,36), 132.12 (C-5), 133.23 (C-33,35), 135.46 (C-34), 137.42 (C-19), 138.32 (C-7), 
141.83 (C-13), 145.85 (C-9), 156.31 (C-27), 160.94 (C-4), 163.37 (C-2), 164.57 (C-30). 




Yield: 75%, mp: 243–46°C. IR (KBr), v, cm
−1: 618 (C-I), 749 (C-Cl), 1315 (C-N), 1260, 
1049 (C-O-C oxadiazole), 1611 (C=N quinazolinone), 1658 (C=N oxadiazole), 1683 (C=O 
quinazolinone), 2921, 2849 (CH2), 3445 (NH). 
1H NMR (400 MHz, DMSO-d6, TMS): δ 3.51 
(s, 2H, H-11), 4.48 (s, 2H, H-25), 6.42 (d, J = 7.96 Hz, 1H, H-14), 6.90 (t, J = 7.4 Hz, 1H, 
H-16), 7.03-7.08 (m, 2H, H-15,22), 7.21 (dd, J = 7.5 Hz, 1.28 Hz, 1H, H-17), 7.24 (d, J = 
8.4 Hz, 1H, H-8), 7.41 (d, J = 8.12 Hz, 2H, H-21,23), 7.62 (d, J = 8.2 Hz, 2H, H-33,35), 
7.68 (d, J = 8.2 Hz, 2H, H-32,36), 7.93 (d, J = 8.4 Hz, 1H, H-7), 8.28 (s, 1H, H-5), 9.12 (bs, 
1H, H-18). 
13C NMR (100 MHz, DMSO-d6, TMS): δ 33.47 (C-11), 42.45 (C-25), 93.38 (C-
6), 116.31 (C-16), 120.56 (C-14), 122.54 (C-10), 123.33 (C-31), 123.97 (C-8), 124.17 (C-
22), 126.60 (C-15), 127.02 (C-12), 127.25 (C-21,23), 129.36 (C-20,24), 131.27 (C-17), 
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(C-13), 142.48 (C-7), 145.76 (C-9), 156.31 (C-27), 161.14 (C-4), 163.49 (C-2), 164.63 (C-
30). Anal. Calcd. for C30H19Cl3IN5O2: C, 50.41; H, 2.68; N, 9.80. Found: C, 50.35; H, 2.76; 
N, 9.77. 
Antimicrobial activity 
The MICs of synthesized compounds were carried out by broth microdilution method as 
described by Rattan [35]. Antibacterial activity was screened against two gram positive 
bacteria (S. aureus MTCC 96, S. pyogenes MTCC 442) and two gram negative bacteria 
(E. coli MTCC 443, P. aeruginosa MTCC 1688). Ampicillin was used as a standard 
antibacterial agent. Antifungal activity was screened against three fungal species C. 
albicans MTCC 227, A. niger MTCC 282 and A. clavatus MTCC 1323. Griseofulvin was 
used as a standard antifungal agent. 
All MTCC cultures were collected from Institute of Microbial Technology, Chandigarh and 
tested against above mentioned known drugs. Mueller hinton broth was used as nutrient 
medium to grow and dilute the drug suspension for the test. Inoculum size for test strain 
was adjust to 10
8 CFU (Colony Forming Unit) per milliliter by comparing the turbidity. 
DMSO was used as diluents to get desired concentration of drugs to test upon standard 
bacterial strains. Serial dilutions were prepared in primary and secondary screening. The 
control tube containing no antibiotic was immediately sub cultured (before inoculation) by 
spreading a loopful evenly over a quarter of plate of medium suitable for the growth of the 
test organism and put for incubation at 37 °C overnight. The tubes were then incubated 
overnight. The MIC of the control organism was read to check the accuracy of the drug 
concentrations. The lowest concentration inhibiting growth of the organism was recorded 
as the MIC. All the tubes not showing visible growth (in the same manner as control tube 
described above) was sub cultured and incubated overnight at 37  °C. The amount of 
growth from the control tube before incubation (which represents the original inoculum) 
was compared. Subcultures might show: similar number of colonies indicating 
bacteriostatic; a reduced number of colonies indicating a partial or slow bactericidal activity 
and no growth if the whole inoculum has been killed. The test must include a second set of 
the same dilutions inoculated with an organism of known sensitivity. Each synthesized 
drug was diluted obtaining 2000 μg/ml concentration, as a stock solution. In primary 
screening 500 μg/ml, 250 μg/ml and 125 μg/ml concentrations of the synthesized drugs 
were taken. The active synthesized drugs found in this primary screening were further 
tested in a second set of dilution against all microorganisms. The drugs found active in 
primary screening were similarly diluted to obtain 100 μg/ml, 50 μg/ml, 25 μg/ml, 12.5 
μg/ml, 6.250 μg/ml, 3.125 μg/ml and 1.5625 μg/ml concentrations. The highest dilution 
showing at least 99 % inhibition is taken as MIC. 
Conclusions 
Aminosubstituted 1,3,4-oxadiazoles 4a,b and 5a,b exhibited very good antimicrobial 
activity. But when they were condensed with benzoxazinone formed oxadiazolyl-
quinazolinone, showed increasing activity. Antimicrobial results were found uneven but 
most of the bromo and iodo derivatives of quinazolinone possessed very good 
antimicrobial activity. Furthermore CH2 link between 3
rd position of quinazolinone and 2
nd 
position of oxadiazole were found most active than other two series. So, it seems from the 190  N. B. Patel and J. C. Patel: 
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antimicrobial results that halogen atom and CH2 link played vital role in increasing 
antimicrobial activity. 
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